AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02561949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Income generating activity program
Description: Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
Study NCT03166449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neomune
Description: Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
Study NCT03166449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin® HP energy
Description: Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
Study NCT03091010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
Study NCT03091010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
Study NCT04973735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY-CovMab
Description: single IV infusion
Study NCT04973735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY-CovMab
Description: single IV infusion
Study NCT04353674 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Patients randomized into this group will receive standard of care for COVID-19 infection
Study NCT04353674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLEDD with a L-MOD
Description: Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
Study NCT03702673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet A
Description: K-877 Controlled Release Tablet A
Study NCT03702673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet B
Description: K-877 Controlled Release Tablet B
Study NCT00389220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent placement
Description: Coronary stent placement
Study NCT00266240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses po bid
Study NCT00266240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study NCT01245036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antituberculous therapy along with steroids
Description: INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
Study NCT00880087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
Study NCT00880087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia
Description: Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
Study NCT03720769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-by-Step
Description: Guided self-help programme delivered through an app/website for the treatment of depression
Study NCT03720769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care as usual
Description: Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
Study NCT02783430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
Study NCT02783430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
Study NCT02783430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
Study NCT02783430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One single perfusion during 40 minutes at the beginning of the inclusion
Study NCT03702049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Community Health Worker TBI (RN/CHW TBI) program
Description: Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
Study NCT03173170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 Infusion
Study NCT03173170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Capsule
Study NCT04413734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
Study NCT04413734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mono-chemotherapy
Description: Gemcitabine plus Cisplatin by intravenous infusion
Study NCT03232255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse (IQP-OLP-101)
Description: Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
Study NCT03702673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet E
Description: K-877 Controlled Release Tablet E
Study NCT02731963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
Study NCT03355209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 0.2 or 0.8 mg/kg/day
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
Study NCT03355209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered twice a day (BID) in equally divided doses.
Study NCT02316158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based support
Description: Comparison between the efficacy between webb-based support and informational support
Study NCT02316158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based support
Description: Comparison between the efficacy between webb-based support and informational support
Study NCT00743509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
Study NCT00427674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] mZINT injection and serial dynamic SPECT imaging
Description: Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
Study NCT04583696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The Investigation of effect on Blood Lipid parameters with walnut addition of Diet
Description: Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
Study NCT00766831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
Study NCT00251433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib, docetaxel, trastuzumab
Description: The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
Study NCT03060837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Parameters
Description: Preoperative Hmg and serum creatinine levels
Study NCT03060837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroperative Parameters
Description: Scope duration, perforation, hemorrhage, etc. complications
Study NCT03060837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Parameters
Description: Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
Study NCT04217655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Description: Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
Study NCT04217655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose computed tomography
Description: Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
Study NCT00396461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCT/LCT (1:1)
Description: Emulsion based on 20% MCT/LCT (50:50 ratio)
Study NCT00396461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT/omega-3 (5:4:1)
Description: Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
Study NCT02212340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fresofol and remifentanil
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Study NCT02212340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane and remifentanil
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Study NCT00850226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT
Description: Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
Study NCT00850226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
Study NCT01813071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1
Study NCT01120769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: single dose
Study NCT01120769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study NCT01158352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation formula
Description: Nutritional supplementation formula
Study NCT01158352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous infusion of lidocaine
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: maintenance of hypnosis during anaesthesia with sevoflurane
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: maintenance of hypnosis during anaesthesia with sevoflurane
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA-TCI
Description: maintenance of hypnosis during anaesthesia with sevoflurane
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA-TCI
Description: maintenance of hypnosis during anaesthesia with sevoflurane
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: administration of 1 g acetaminophen for postoperative analgesia
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administration of 1 g acetaminophen for postoperative analgesia
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: administration of tramadol for postoperative analgesia
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: administration of tramadol for postoperative analgesia
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
Study NCT02839668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
Study NCT02839668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
Study NCT02839668 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
Study NCT04815252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIME
Description: CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
Study NCT01267006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
Study NCT01267006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
Study NCT00183586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family therapy (FT)
Description: FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
Study NCT00183586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy (IT)
Description: IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
Study NCT04115709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Caresystem device with advice
Description: Beacon Caresystem device provides ventilator settings advice to Doctors
Study NCT04115709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beacon Caresystem device without advice activated
Description: Beacon Caresystem device does not give ventilator settings advice
Study NCT03351231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986242
Description: Specified dose on specified days
Study NCT03351231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02240563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Study NCT03702673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR Tablet
Description: K-877 Immediate Release Tablet
Study NCT02240563 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non laser ordinary red light
Study NCT00494780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
Study NCT00494780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
Study NCT00494780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
Study NCT01884688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENK Cell Infusion
Description: Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
Study NCT03116061 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study NCT04727684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.